Advanced Enzyme Technologies (ADVENZYMES) Q3 25/26 earnings summary

Executive summary

• Q3 FY26 consolidated revenue was INR 1,719 million, up 2% year-over-year but down 7% sequentially; nine-month revenue grew 15% year-over-year to INR 5,424 million.

• Q3 FY26 EBITDA declined 11% year-over-year to INR 494 million, while PAT increased 11% to INR 432 million; nine-month PAT rose 20% to INR 1,284 million.

• Human Healthcare contributed 56% of Q3 revenue, with Animal Healthcare and Bioprocessing showing strong growth.

• Board approved collaboration for a Group Captive Wind Power Plant via SPV, with up to 26% equity investment, and discontinued plans for a group captive solar power project.

• Approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

Financial highlights

• Q3 FY26 consolidated revenue: INR 1,719 million (+2% YoY, -7% QoQ); nine-month revenue: INR 5,424 million (+15% YoY).

• Q3 FY26 EBITDA: INR 494 million (-11% YoY, -18% QoQ); nine-month EBITDA: INR 1,658 million (+11% YoY).

• Q3 FY26 PAT: INR 432 million (+11% YoY, -3% QoQ); nine-month PAT: INR 1,284 million (+20% YoY).

• Consolidated net profit for Q3 FY26: INR 582.91 million, compared to INR 530.21 million YoY.

• JC Biotech Q3 PAT was negative due to annual maintenance; nine-month PAT up 39% YoY.

Outlook and guidance

• Management expects strong growth to persist across all business segments, focusing on operational resilience and adaptation to market dynamics.

• Double-digit growth (13–15%) targeted over the next 3–5 years, with healthcare remaining a top focus.

• Focus areas include expanding animal nutrition, probiotics, bio-catalysis, and baking solutions, with plans to introduce new products and strengthen global distribution.

• U.S. market outlook is improving with more inquiries and normalization of tariffs, though margin impact remains under watch.

• Expansion into renewable energy through wind power investment.